NCT06930092 RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy
| NCT ID | NCT06930092 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Ischemic Cardiomyopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 158 participants |
| Start Date | 2025-08-03 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 158 participants in total. It began in 2025-08-03 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and multivessel coronary artery disease.
Eligibility Criteria
Inclusion Criteria: * Subject must be ≥ 19 years * Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. * Subject with LV ejection fraction \<40% from cardiac MRI * Subject with multivessel disease in major epicardial coronary artery disease or their major branches (vessel size of 2.5 mm or more than 2.5mm) considering coronary revascularization Exclusion Criteria: * Subjects with more than 50% transmural extent of infarction on GE-MRI in more than 25% of the dysfunctional myocardial segments * Subject with suspicious of other cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyopathy etc.) * Subject with recent myocardial infarction within 4 weeks * Subject with recent fatal arrhythmia (VT or VF) within 4 weeks * Subject with hemodynamically unstable state * Subject with complex coronary artery lesions, such as chronic total occlusions, in which complete revascularization is considered unfeasible * Subject for whom coronary artery bypass surgery is prioritized over coronary artery intervention * Subject with severe valvular heart disease requiring open heart surgery * Subject with history of coronary artery bypass surgery or valve surgery * Subject with expected life expectancy of less than 1 year * Subject considered ineligible for this study based on the investigator's discretion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06930092 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Ischemic Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06930092 currently recruiting?
Yes, NCT06930092 is actively recruiting participants. Contact the research team at cardiol.intv@gmail.com for enrollment information.
Where is the NCT06930092 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06930092 clinical trial?
NCT06930092 is sponsored by Seoul National University Hospital. The trial plans to enroll 158 participants.